Articles tagged with Glioblastomas
Researchers at Cedars-Sinai Medical Center found that combining an anti-tumor vaccine with chemotherapy significantly extended patient survival to 26 months on average. The treatment, which involves dendritic-cell immunotherapy, was shown to slow tumor growth and increase the effectiveness of chemotherapy.
A phase III study uses IL13-PE38QQR, a hybrid protein that attaches to specific receptors on tumor cells, to target residual GBM brain tumors. The treatment, convection-enhanced delivery, facilitates infusion of the drug into the brain, bypassing the blood-brain barrier.
Cedars-Sinai researchers found that laminin-8 expression is linked to tumor aggressiveness and patient outcomes. High levels of laminin-8 are associated with shorter survival times and increased risk of tumor recurrence.
Scientists at Cedars-Sinai Medical Center used gene array technology to analyze thousands of genes in malignant brain tumor samples. They identified a critical step in the development of glioblastoma multiforme, which may improve patient prognosis and lead to effective therapies.
Researchers at Penn State's College of Medicine have identified a marker for certain types of brain tumors, including glioblastoma multiforme (GBM), which are the most prevalent and difficult-to-manage. The marker, interleukin 13 receptor, is present in over 90% of patients with GBM, making it a valuable diagnostic tool.
Researchers at Thomas Jefferson University are conducting a gene therapy trial for glioblastoma, a form of brain cancer. The trial aims to delay disease progression and improve quality of life for patients, offering a potential cure for the deadliest type of brain tumor.